NASDAQ:ACIU AC Immune (ACIU) Stock Price, News & Analysis $2.77 -0.02 (-0.72%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$2.82 +0.05 (+1.81%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AC Immune Stock (NASDAQ:ACIU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AC Immune alerts:Sign Up Key Stats Today's Range$2.74▼$2.9050-Day Range$2.56▼$3.4052-Week Range$1.60▼$4.00Volume224,826 shsAverage Volume264,887 shsMarket Capitalization$281.90 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingHold Company Overview AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates. Since its founding in 2003, AC Immune has advanced multiple programs into clinical development. Its SupraAntigen™ platform is designed to generate active vaccines that elicit a targeted immune response against disease-associated proteins, while its Morphomer™ platform discovers small molecules that bind misfolded proteins and inhibit their toxic aggregation. Among the company’s leading assets are anti-tau vaccine candidates in mid-stage clinical trials and small-molecule inhibitors aimed at disrupting toxic oligomer formation. AC Immune maintains collaborations and strategic partnerships with major pharmaceutical firms to accelerate development and expand global reach. Notable alliances include research agreements with Janssen Pharmaceuticals and UCB to co-develop immunotherapies for Alzheimer’s and Parkinson’s diseases, as well as partnerships with Eli Lilly and Genentech focused on diagnostic imaging agents. These collaborations strengthen AC Immune’s ability to advance its pipeline while accessing broader regulatory and commercialization expertise. Under the leadership of CEO Dr. Andrea Pfeifer, who co-founded the company and has guided its growth since inception, AC Immune continues to invest in innovative approaches to neurodegeneration. The company’s integrated research and development model, combining both therapeutic and diagnostic strategies, aims to deliver precision solutions that address unmet medical needs in aging populations across North America, Europe and Asia. AI Generated. May Contain Errors. Read More AC Immune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreACIU MarketRank™: AC Immune scored higher than 50% of companies evaluated by MarketBeat, and ranked 614th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingAC Immune has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAC Immune has a consensus price target of $7.50, representing about 170.8% upside from its current price of $2.77.Amount of Analyst CoverageAC Immune has only been the subject of 3 research reports in the past 90 days.Read more about AC Immune's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AC Immune are expected to grow in the coming year, from ($0.68) to $0.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AC Immune is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AC Immune is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAC Immune has a P/B Ratio of 5.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AC Immune's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.12% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 12.91, which indicates bearish sentiment.Change versus previous monthShort interest in AC Immune has recently increased by 3.43%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAC Immune does not currently pay a dividend.Dividend GrowthAC Immune does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.80 News SentimentAC Immune has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for AC Immune this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for ACIU on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AC Immune insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,900.00 in company stock.Percentage Held by Insiders4.60% of the stock of AC Immune is held by insiders.Percentage Held by Institutions51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AC Immune's insider trading history. Receive ACIU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACIU Stock News HeadlinesAC Immune (NASDAQ:ACIU) CEO Sells $27,900.00 in Stock3 hours ago | insidertrades.comTop Executive Move at AC Immune SA Sparks Fresh Investor BuzzMay 18 at 10:31 PM | tipranks.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 19 at 1:00 AM | Banyan Hill Publishing (Ad)AC Immune Sets June AGM and Reshapes Leadership as Long-Serving CEO RetiresMay 15, 2026 | tipranks.comDavos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and CareMay 15, 2026 | globenewswire.comAC Immune CEO and Co-Founder Andrea Pfeifer to Retire at June 11 AGM; Board Chair Martin Zügel Named Interim ChiefMay 12, 2026 | tipranks.comAC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGMMay 12, 2026 | globenewswire.comAC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration PipelineApril 30, 2026 | tipranks.comSee More Headlines ACIU Stock Analysis - Frequently Asked Questions How have ACIU shares performed this year? AC Immune's stock was trading at $3.14 at the start of the year. Since then, ACIU stock has decreased by 11.8% and is now trading at $2.77. How were AC Immune's earnings last quarter? AC Immune (NASDAQ:ACIU) announced its quarterly earnings data on Thursday, April, 30th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01. The business had revenue of $1.40 million for the quarter, compared to analyst estimates of $0.33 million. AC Immune had a negative net margin of 1,788.02% and a negative trailing twelve-month return on equity of 125.26%. When did AC Immune IPO? AC Immune (ACIU) raised $72 million in an initial public offering on Friday, September 23rd 2016. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. Who are AC Immune's major shareholders? AC Immune's top institutional investors include Renaissance Technologies LLC (0.61%), Arrowstreet Capital Limited Partnership (0.40%) and Dimensional Fund Advisors LP (0.38%). View institutional ownership trends. How do I buy shares of AC Immune? Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AC Immune own? Based on aggregate information from My MarketBeat watchlists, some other companies that AC Immune investors own include Meta Platforms (META), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Tesla (TSLA), Advanced Micro Devices (AMD) and Canopy Growth (CGC). Company Calendar Last Earnings4/30/2026Today5/19/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ACIU's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACIU CIK1651625 Webwww.acimmune.com Phone(121) 345-9121Fax41-21-345-9120Employees140Year Founded2003Price Target and Rating Average Price Target for AC Immune$7.50 High Price Target$8.00 Low Price Target$7.00 Potential Upside/Downside+170.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$85.03 million Net Margins-1,788.02% Pretax Margin-1,796.18% Return on Equity-125.26% Return on Assets-40.85% Debt Debt-to-Equity Ratio0.11 Current Ratio0.87 Quick Ratio1.02 Sales & Book Value Annual Sales$4.31 million Price / Sales65.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book5.13Miscellaneous Outstanding Shares101,770,000Free Float97,092,000Market Cap$281.90 million OptionableOptionable Beta1.65 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ACIU) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
